Stock AnalizRevolution Medicines (RVMD) earnings for the quarter ended September 2026: EPS beats estimates
Revolution Medicines reported results for the quarter ended September 2026 on November 4, 2026. Adjusted earnings per share came in at -$1.90 against the analysts’ average forecast of -$2.38, a beat of 20.2%.
Revenue for the quarter was $198 million.
The market’s verdict: the stock fell 8.5% on the first trading day after the report.
The last four quarters
Revolution Medicines has beaten the analysts’ EPS forecast in 1 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | -$1.90 | -$2.38 | +20.2% | — | −8.5% |
| Jun 2026 | -$3.06 | -$2.06 | −48.8% | — | +2.2% |
| Mar 2026 | -$2.29 | -$1.84 | −24.6% | — | −3.2% |
| Dec 2025 | -$1.86 | -$1.56 | −18.9% | — | −2.6% |
What comes next
Analysts expect EPS of -$1.09 for the next quarter on average and -$8.30 for the fiscal year ending December 31, 2026.
The average analyst price target is $274.84, 60% above the current price of $172.29.
Valuation and score
Revolution Medicines scores 0.6 out of 5 overall on Stock Analiz (weak). Full Revolution Medicines analysis with 10 years of financials
Frequently asked questions
What was Revolution Medicines’s EPS for the quarter ended September 2026?
-$1.90 adjusted per share, against an analyst consensus of -$2.38.
How much revenue did Revolution Medicines report?
$198 million.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.